Literature DB >> 23253414

PAR-1 inhibitor antiplatelet agents: performance below par?

Arun Natarajan1, Refai Showkathali, Kare Tang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23253414      PMCID： PMC3860775          DOI： 10.1016/j.ihj.2012.09.003

Source DB:  PubMed          Journal:  Indian Heart J        ISSN： 0019-4832


× No keyword cloud information.
  20 in total

1.  Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.

Authors:  M L Kahn; M Nakanishi-Matsui; M J Shapiro; H Ishihara; S R Coughlin
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

Review 2.  Promises of PAR-1 inhibition in acute coronary syndrome.

Authors:  Sergio Leonardi; Pierluigi Tricoci; Kenneth W Mahaffey
Journal:  Curr Cardiol Rep       Date:  2012-02       Impact factor: 2.931

3.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Authors:  Pierluigi Tricoci; Zhen Huang; Claes Held; David J Moliterno; Paul W Armstrong; Frans Van de Werf; Harvey D White; Philip E Aylward; Lars Wallentin; Edmond Chen; Yuliya Lokhnygina; Jinglan Pei; Sergio Leonardi; Tyrus L Rorick; Ann M Kilian; Lisa H K Jennings; Giuseppe Ambrosio; Christoph Bode; Angel Cequier; Jan H Cornel; Rafael Diaz; Aycan Erkan; Kurt Huber; Michael P Hudson; Lixin Jiang; J Wouter Jukema; Basil S Lewis; A Michael Lincoff; Gilles Montalescot; José Carlos Nicolau; Hisao Ogawa; Matthias Pfisterer; Juan Carlos Prieto; Witold Ruzyllo; Peter R Sinnaeve; Robert F Storey; Marco Valgimigli; David J Whellan; Petr Widimsky; John Strony; Robert A Harrington; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

4.  Vorapaxar in the secondary prevention of atherothrombotic events.

Authors:  David A Morrow; Eugene Braunwald; Marc P Bonaca; Sebastian F Ameriso; Anthony J Dalby; Mary Polly Fish; Keith A A Fox; Leslie J Lipka; Xuan Liu; José Carlos Nicolau; A J Oude Ophuis; Ernesto Paolasso; Benjamin M Scirica; Jindrich Spinar; Pierre Theroux; Stephen D Wiviott; John Strony; Sabina A Murphy
Journal:  N Engl J Med       Date:  2012-03-24       Impact factor: 91.245

5.  Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents.

Authors:  Samuel Chackalamannil; Yan Xia; William J Greenlee; Martin Clasby; Darìo Doller; Hsingan Tsai; Theodros Asberom; Michael Czarniecki; Ho-Sam Ahn; George Boykow; Carolyn Foster; Jacqueline Agans-Fantuzzi; Matthew Bryant; Janice Lau; Madhu Chintala
Journal:  J Med Chem       Date:  2005-09-22       Impact factor: 7.446

6.  Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial.

Authors:  Michelle L O'Donoghue; Deepak L Bhatt; Stephen D Wiviott; Shaun G Goodman; Desmond J Fitzgerald; Dominick J Angiolillo; Shinya Goto; Gilles Montalescot; Uwe Zeymer; Philip E Aylward; Victor Guetta; Dariusz Dudek; Rafal Ziecina; Charles F Contant; Marcus D Flather
Journal:  Circulation       Date:  2011-04-18       Impact factor: 29.690

7.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

Authors:  Ioannis Iakovou; Thomas Schmidt; Erminio Bonizzoni; Lei Ge; Giuseppe M Sangiorgi; Goran Stankovic; Flavio Airoldi; Alaide Chieffo; Matteo Montorfano; Mauro Carlino; Iassen Michev; Nicola Corvaja; Carlo Briguori; Ulrich Gerckens; Eberhard Grube; Antonio Colombo
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

8.  Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke.

Authors:  Yukito Shinohara; Shinya Goto; Masaki Doi; Peder Jensen
Journal:  J Stroke Cerebrovasc Dis       Date:  2010-10-14       Impact factor: 2.136

9.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

Authors:  Deepak L Bhatt; Keith A A Fox; Werner Hacke; Peter B Berger; Henry R Black; William E Boden; Patrice Cacoub; Eric A Cohen; Mark A Creager; J Donald Easton; Marcus D Flather; Steven M Haffner; Christian W Hamm; Graeme J Hankey; S Claiborne Johnston; Koon-Hou Mak; Jean-Louis Mas; Gilles Montalescot; Thomas A Pearson; P Gabriel Steg; Steven R Steinhubl; Michael A Weber; Danielle M Brennan; Liz Fabry-Ribaudo; Joan Booth; Eric J Topol
Journal:  N Engl J Med       Date:  2006-03-12       Impact factor: 91.245

Review 10.  Clinical aspects of platelet inhibitors and thrombus formation.

Authors:  Telly A Meadows; Deepak L Bhatt
Journal:  Circ Res       Date:  2007-05-11       Impact factor: 17.367
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.